Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)

Sponsor
Stem Cells Arabia (Other)
Overall Status
Unknown status
CT.gov ID
NCT03069209
Collaborator
(none)
50
1
1
84
0.6

Study Details

Study Description

Brief Summary

This is an open label, single arm, single center investigation to assess the safety and efficacy of purified adult autologous bone marrow derived specific populations of stem cells and mesenchymal stem cells injected into the ovaries (intraovarian injection), through a 12 week follow-up period. The investigators' chosen model of study is based on increasing the efficiency of the approach by choosing an autologous model which preserves the genetic composition of an individual that is vital in infertility conditions. Additionally the approach involves transplanting a combination of specific purified stem cell types which all aid in ovarian function recovery.

Condition or Disease Intervention/Treatment Phase
  • Biological: Stem Cells
Phase 1/Phase 2

Detailed Description

Premature ovarian failure (POF) is characterized as hypergonadotropic ovarian failure mostly prevalent before age 40. It is astonishingly frequent and affects around 1% of women below the age of 40. The clinical findings include amenorrhea and abnormally high levels of luteinizing (LH) and follicle stimulating hormone (FSH). The etiology of POF is unidentified in the majority of cases. It can occur due to a combination of genetics, immunological diseases, and environmental factors. POF is characterized by lack of secondary follicles, arrested folliculogenesis, decreased estrogen levels, and female infertility.

Currently, no available therapeutic intervention has been verified effective in retrieving fertility in patients with POF. Several trials at ovarian stimulation are typically ineffective. Consequently, the diagnosis of POF can cause great physical and emotional distress among patients. Hence, there is serious need to develop innovative treatment plans for POF.

The latest research shows that reduced ovarian reserve is caused by aging of the niche rather than a defect in germ cell lines. Current scientific evidence suggests that bone marrow-derived mesenchymal stem cells (BMSCs) could repair injured tissues and holds great promise in treating many diseases including male and female infertility.

The uniqueness of this study is demonstrated in the transplantation of purified specific populations of autologous bone marrow derived stem cells and mesenchymal stem cells (BMSCs) into patients with POF without in vitro expansion or culture, with minimal manipulation. Stem cells are withdrawn and transplanted back into the patient on the same day of the procedure, thus presenting the highest safety and efficacy parameters.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Transplantation of Specific Populations of Bone Marrow-Derived Stem Cells and Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure.
Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Jan 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stem Cells

Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.

Biological: Stem Cells
Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.

Outcome Measures

Primary Outcome Measures

  1. Return of menstrual cycle [6 months]

    Return of menses in a woman with previous ameneorrhea for at least 6 months before recruitment.

Secondary Outcome Measures

  1. Pregnancy [12 months]

    Occurrence of pregnancy during the 12 months follow-up period

  2. FSH levels [12 months]

    Normalization of FSH levels

  3. Follicular function [12 months]

    development of ovarian follicles to a size at least 18 mm in diameter

  4. Endometrium thickness [12 months]

    Increase in endometrial thickness

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 39 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female

  • Age : 20-39

  • FSH>20

Exclusion Criteria:
  • Thyroid dysfunction

  • Immunological Conditions

  • Past history of malignancy/cemotherapy/radiotherapy

  • Infectious diseases: HIV+, hepatitis B+, C+

  • Abnormal karyotype

  • Previous surgical management of ovarian pathology

  • Severe endometriosis

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stem Cells Arabia Amman Jordan 11953

Sponsors and Collaborators

  • Stem Cells Arabia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stem Cells Arabia
ClinicalTrials.gov Identifier:
NCT03069209
Other Study ID Numbers:
  • SCA-POF1
First Posted:
Mar 3, 2017
Last Update Posted:
May 17, 2018
Last Verified:
May 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2018